Drugs / EVAZARSEN
EVAZARSEN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04083222 | Nov 2019 → Jul 2020 | hypertensive disorder | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 2 | NCT03714776 | Jan → Nov 2019 | hypertensive disorder | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVAZARSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095456 ↗ |
| Known as | IONIS-AGT-LRx | “This study evaluated the effect of ISIS 757456 (IONIS-AGT-LRx) on plasma angiotensinogen (AGT) and systolic blood pressure (SBP)” NCT04083222 ↗ |
| Known as | ISIS 757456 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04083222 ↗ |
| Known as | ISIS-654472 5'-GALNAC CONJUGATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095456 ↗ |
| Route | Subcutaneous | “ISIS 757456 administered as SC injection.” NCT04083222 ↗ |